View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 13, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,851,990
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	150 Allen Road
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Basking Ridge
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07920
City Area Code	973
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 15,620,496	$ 13,563,791
Marketable securities		10,495,350
Accounts receivable, net	272,044	496,140
Inventories, net	664,371	890,992
Prepaid expenses and other current assets	838,735	1,087,111
Total current assets	17,395,646	26,533,384
Inventories, non-current	6,247,439	6,020,180
Property and equipment, net	316,706	345,236
Operating lease right of use assets	1,336,508	1,430,641
Other assets	1,067,965	1,132,238
Total assets	26,364,264	35,461,679
Current liabilities:
Accounts payable	3,646,414	5,208,979
Accrued expenses	3,186,324	3,337,379
Note payable		111,878
Current portion of operating lease liabilities	514,917	486,445
Total current liabilities	7,347,655	9,144,681
Noncurrent liabilities:
Operating lease liabilities	1,282,827	1,419,880
Total liabilities	8,630,482	10,564,561
Commitments and contingencies
Stockholders' equity:
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at March 31, 2020 and December 31, 2019; 30,421,427 issued and outstanding at March 31, 2020 and 29,835,183 shares issued and outstanding at December 31, 2019	30,422	29,835
Additional paid-in capital	108,496,344	107,752,066
Accumulated deficit	(91,438,447)	(83,479,098)
Accumulated other comprehensive income/(loss)	9,853	(41,295)
Total stockholders' equity	17,098,172	24,261,508
Noncontrolling interest	635,610	635,610
Total equity	17,733,782	24,897,118
Total liabilities and stockholders' equity	$ 26,364,264	$ 35,461,679

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	30,421,427	29,835,183
Common stock, shares outstanding	30,421,427	29,835,183

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net sales	$ 733,771	$ 409,601
Cost of goods sold	298,115	157,791
Gross profit	435,656	251,810
Operating expenses:
Research and development	1,523,114	3,459,823
Selling, general and administrative	6,560,726	11,002,999
Restructuring and other severance related charges	365,000	0
Total operating expenses	8,448,840	14,462,822
Loss from operations	(8,013,184)	(14,211,012)
Other (income)/expense
Interest and other income, net	(62,976)	(366,174)
Other expense	9,141	16,692
Total other (income)/expense	(53,835)	(349,482)
Loss before income taxes	(7,959,349)	(13,861,530)
Provision for income taxes	0	0
Net loss from operations	$ (7,959,349)	$ (13,861,530)
Net loss per share of common stock - Basic and Diluted (see Note 14)	$ (0.27)	$ (0.47)
Weighted average common shares outstanding - Basic and Diluted (see Note 14)	29,774,226	29,319,318

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss from operations	$ (7,959,349)	$ (13,861,530)
Other comprehensive income:
Foreign currency translation adjustment	45,322	43,575
Unrealized gains on securities, net of taxes as applicable	5,826	40,138
Other comprehensive income	51,148	83,713
Comprehensive loss	$ (7,908,201)	$ (13,777,817)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)

Total

Common Stock

Additional Paid-in Capital

Accumulated Deficit

Accumulated Other Comprehensive Income

Total Stockholders' Equity

Noncontrolling Interest

Balances, beginning of period at Dec. 31, 2018

$ 66,185,701

$ 29,450

$ 103,791,013

$ (38,331,215)

$ 60,843

$ 65,550,091

$ 635,610

Balances, beginning of period, shares at Dec. 31, 2018

29,450,035

Net loss

(13,861,530)

Other comprehensive income

83,713

Issuance of warrants in settlement of lawsuit

16,692

Issuance of stock related to employee compensation plans, net of forfeitures

$ 183

(183)

Issuance of stock related to employee compensation plans, net of forfeitures, shares

183,205

Stock based compensation

744,032

Balances, end of period at Mar. 31, 2019

53,168,608

$ 29,633

104,551,554

(52,192,745)

144,556

52,532,998

635,610

Balances, end of period, shares at Mar. 31, 2019

29,633,240

Balances, beginning of period at Dec. 31, 2018

66,185,701

$ 29,450

103,791,013

(38,331,215)

60,843

65,550,091

635,610

Balances, beginning of period, shares at Dec. 31, 2018

29,450,035

Net loss

(45,100,000)

Balances, end of period at Dec. 31, 2019

24,897,118

$ 29,835

107,752,066

(83,479,098)

(41,295)

24,261,508

635,610

Balances, end of period, shares at Dec. 31, 2019

29,835,183

Net loss

(7,959,349)

Other comprehensive income

51,148

Equity financing commitment fee

^[1]

$ 462

(462)

Equity financing commitment fee, shares

^[1]

461,676

Issuance of stock related to employee compensation plans, net of forfeitures

$ 125

(125)

Issuance of stock related to employee compensation plans, net of forfeitures, shares

124,568

Stock based compensation

744,865

Balances, end of period at Mar. 31, 2020

$ 17,733,782

$ 30,422

$ 108,496,344

$ (91,438,447)

$ 9,853

$ 17,098,172

$ 635,610

Balances, end of period, shares at Mar. 31, 2020

30,421,427

[1]	Reflects commitment shares issued in accordance with the Company's equity facility purchase agreement with Lincoln Park Capital. For additional information see Note 13. Stock Purchase Agreement

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss from operations	$ (7,959,349)	$ (13,861,530)	$ (45,100,000)	$ (55,800,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	744,865	744,032
Depreciation and amortization	97,419	25,522
Amortization of marketable securities discount	1,176	(200,302)
Cloud computing arrangement implementation costs		(618,044)
Net noncash lease expense	(21,581)	117,579
Noncash portion of litigation settlement		16,692
Other	10,937	43,343
Changes in operating assets and liabilities:
Accounts receivable, net	224,096	(20,736)
Inventories	(638)	(1,639,862)
Prepaid expenses and other current assets	238,376	830,406
Accounts payable	(1,562,615)	(719,463)
Accrued expense and other current liabilities	(151,055)	(1,117,793)
Net cash used in operating activities	(8,378,369)	(16,400,156)
Cash flows from investing activities:
Purchase of marketable securities		(12,110,420)
Proceeds from maturities of marketable securities	10,500,000	27,901,000
Purchases of property and equipment		(37,318)
Net cash provided by investing activities	10,500,000	15,753,262
Cash flows from financing activities:
Repayments of note payable	(111,878)
Net cash used in financing activities	(111,878)
Effect of changes in exchange rates on cash and cash equivalents	46,952	396
Net increase/(decrease) in cash and cash equivalents	2,056,705	(646,498)
Cash and cash equivalents – beginning of period	13,563,791	7,600,284	7,600,284
Cash and cash equivalents – end of period	$ 15,620,496	6,953,786	$ 13,563,791	$ 7,600,284
Supplemental schedule of noncash activity:
Prepaid lease payments included in right of use assets		93,261
Capitalized cloud computing arrangement costs included in accrued expenses and other liabilities		$ 167,798

The Company

3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

The Company

Note 1. The Company

electroCore, Inc. (“electroCore” or the “Company”) is a medical device company, engaged in the commercialization and development of a range of patient administered non-invasive Vagus Nerve Stimulation (“nVNS”) therapies. electroCore was founded in 2005 and its focus currently is on primary headache conditions (migraine and cluster headache).

electroCore, headquartered in New Jersey, has two wholly owned subsidiaries: electroCore Germany GmbH, and electroCore UK Ltd. Effective April 30, 2020, the Company has ceased its operations in Germany. In addition, an affiliate, electroCore (Aust) Pty Limited, or electroCore Australia, is subject to electroCore’s control on a basis other than voting interests and is a variable interest entity, or VIE, for which electroCore is the primary beneficiary.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

(a)	Basis of Presentation

The accompanying consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2020. The results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.

(b)	Principles of Consolidation

The accompanying consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. electroCore Australia, a VIE for which electroCore is the primary beneficiary, is also consolidated with the non-controlled equity presented as non-controlling interest. All intercompany balances and transactions have been eliminated in consolidation.

(c)	Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of fixed assets, allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns; valuation of inventory, property and equipment, stock compensation, and contingencies.

(d)	Credit Losses on Financial Instruments

In June 2016, the FASB issued guidance on the measurement of credit losses which requires measurement and recognition of expected credit losses for financial assets, including trade receivables held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. The guidance is effective beginning January 1, 2020. The Company adopted this guidance and determined the impact was immaterial on the consolidated to the financial statements.

(e)	Fair Value Measurement

In August 2018, the FASB issued guidance which modifies the disclosure requirements for fair value measurements. The guidance is effective for the year ended December 31, 2020. The Company adopted this guidance which was properly reflected in the consolidated financial statements. There were no material changes to the prior disclosure.

(f)	Recent Accounting Pronouncements Not Yet Adopted

In December 2019, the FASB issued an update to simplify the accounting for income taxes and improve consistent application by clarifying or amending existing guidance. This guidance is effective for the year ended December 31, 2021. The Company does not expect this guidance to have a material impact on its consolidated financial statements upon adoption.

Risks and Uncertainties

3 Months Ended

Mar. 31, 2020

Risks And Uncertainties [Abstract]

Risks and Uncertainties

Note 3. Risks and Uncertainties

Liquidity Risks

The Company is subject to risks common to emerging medical device companies, including uncertainties related to commercialization of products and failing to secure additional funding.

The Company has experienced significant net losses, and it expects to continue to incur losses for the near future as it operates its sales and marketing infrastructure, and works to increase market acceptance of its gammaCore therapy for the acute treatment of episodic cluster headache, or eCH, the prevention of cluster headache, and the preventive and acute treatment of migraine. The Company has never been profitable and has incurred net losses in each year since its inception.

The Company incurred net losses of $8.0 million and $13.9 million for the three months ended March 31, 2020 and March 31, 2019, respectively The Company incurred net losses of $45.1 million and $55.8 million for the years ended December 31, 2019 and 2018, respectively. As of March 31, 2020, its accumulated deficit was $91.4 million.

On March 27, 2020, the Company and Lincoln Park Capital Fund, LLC, or Lincoln Park, entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25,000,000, subject to certain significant limitations and conditions set forth in the purchase agreement.

In April 2020, the Company received aggregate proceeds of approximately $5.0 million from sales of common stock to Lincoln Park and a private placement transaction to certain affiliates and existing shareholders of the Company, including some members of the Company’s Board of Directors.

In May 2020, the Company entered into a loan for approximately $1.4 million under the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of certain expenses and loan recipients maintaining their payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the Small Business Administration (“SBA”) may adopt. No assurance can be provided that the Company will obtain forgiveness of the Note in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for re-payment of some or all of the loan.

In May 2020, the Company received proceeds of approximately $1.2 million from a sale of state tax NOLs under the New Jersey Technology Business Tax Certificate Transfer (NOL) Program.

The Company’s expected cash requirements for 2020 and beyond are based on the commercial success of its products and its ability to reduce operating expenses. There are significant risks and uncertainties as to its ability to achieve these operating results, including as a result of the adverse impact on its business from the COVID-19 pandemic. Due to these risks and uncertainties, the Company may need to reduce its activities significantly more than in its current operating plan and cash flow projections assume in order to fund its operations beyond one year of the date these financial statements are issued. There can be no assurance that the Company will have sufficient cash flow and liquidity to fund its planned activities, which could force it to significantly reduce or curtail our activities and, ultimately, potentially cease operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

Even if the Company is not required to curtail its activities sooner, its ability to execute its operating plan beyond the first quarter of 2021 depends on its ability to increase revenue, reduce operating expenses and obtain additional funding through the sale of equity and or debt securities, a strategic transaction or otherwise. There is no assurance that the Company will generate sufficient funding through its operating results or sale of securities, raising substantial doubt about the Company’s ability to continue as a going concern within one year of the date these financial statements are issued. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Concentration of Revenue Risks

The Company earns a significant amount of its revenue (i) in the U.S. from the Department of Veterans Affairs and Department of Defense pursuant to its qualifying contract under the Federal Supply Schedule and open market sales to individual Department of Veterans Affairs facilities and (ii) in the United Kingdom from the National Health Service. Net sales from these two channels represented 95% and 30% of the Company’s net sales for the three months ended March 31, 2020 and 2019, respectively.

Foreign Currency Exchange Risks

The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its foreign currency denominated assets, liabilities, and cash flows.

COVID-19 Risks and Uncertainties

The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact business partners. While the Company began to experience disruptions during the three months ended March 31, 2020 from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.

In addition, because the COVID-19 pandemic affected, among other things, our access to prescribing physicians and their access to headache patients, on March 23, 2020 we suspended our earlier full-year revenue guidance until we could better understand the trajectory of our business, as well as announcing a reduction in our activities, and adjusting our cash runway expectations in response to the potential adverse impact cause by the COVID-19 pandemic. Compared to our earlier expectations, we believe that our results for the quarter ended March 31, 2020 reflect a negative impact from, among other things, the global pandemic. Moreover, our expectations for the remainder of 2020 have also been adversely affected by both the uncertainty and potential negative impact of the global pandemic, which we believe may also have had an adverse effect on our access to debt and equity capital markets. Depending upon the duration and severity of the pandemic, the continuing effect on our results and outlook over the long term remains somewhat uncertain.

Revenue Recognition

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Revenue Recognition

Note 4. Revenue Recognition

Geographical Net Sales

The following table presents net sales disaggregated by geographic area:

	For the three months ended March 31,
	2020		2019
Geographic Market
United States	$	457,559	$	276,465
United Kingdom		245,466		90,584
Germany		30,746		35,836
Other		-		6,716
Total Net Sales	$	733,771	$	409,601

Performance Obligations

Revenue, net of distribution discounts, vouchers, rebates, returns, and co-payment assistance is solely generated from the sales of gammaCore products. Revenue is recognized when delivery of the product is completed. The Company deems control to have transferred upon the completion of delivery because that is the point in which (1) it has a present right to payment for the product, (2) it has transferred the physical possession of the product, (3) the customer has a legal title to the product, (4) the customer has risks and rewards of ownership and (5) the customer has accepted the product. After the products have been delivered and control has transferred, the Company has no remaining unsatisfied performance obligations.

Revenue is measured based on the consideration that the Company expects to receive in exchange for gammaCore, which represents the transaction price. The transaction price includes the fixed per-unit price of the product and variable consideration in the form of trade credits, rebates, and co-payment assistance. The per-unit price is based on the Company’s established wholesale acquisition cost less a contractually agreed upon distributor discount with the customer.

Trade credits are discounts that are contingent upon a timely remittance of payment and are estimated based on historical experience.

Agreed upon payment terms with customers are within 120 days of shipment. Accordingly, contracts with customers do not include a significant financing component.

Contract Balances

The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Accordingly, under ASC 606, the Company’s contracts with customers did not give rise to contract assets or liabilities during the three months ended March 31, 2020 and 2019.

Cash, Cash Equivalents and Marketable Securities

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Cash, Cash Equivalents and Marketable Securities

Note 5. Cash, Cash Equivalents and Marketable Securities

The following tables summarize the Company’s cash, cash equivalents and marketable securities as of March 31, 2020 and December 31, 2019.

As of March 31, 2020
	Amortized Cost		Unrealized Gain		Unrealized (Loss)		Fair Value
Cash and cash equivalents	$	15,614,320	$	6,176	$	—	$	15,620,496

As of December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	13,564,252	$	—	$	(461	)	$	13,563,791

U.S. Treasury Bonds	$	10,494,539	$	811	$	-		$	10,495,350
Total marketable securities	$	10,494,539	$	811	$	-		$	10,495,350

Total cash, cash equivalents, and marketable securities	$	24,058,791	$	811	$	(461	)	$	24,059,141

Fair Value Measurements

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 6. Fair Value Measurements

Financial assets and liabilities carried at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy:

•	Level 1—Quoted prices in active markets for identical assets or liabilities.

•

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows:

			Fair Value Hierarchy
March 31, 2020	Total		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents	$	15,620,496	$	15,620,496	$	—	$	—
Total	$	15,620,496	$	15,620,496	$	—	$	—

December 31, 2019
Assets
Cash and cash equivalents	$	13,563,791	$	13,563,791	$	—	$	—
Marketable Securities:
U.S. treasury bonds		10,495,350		10,495,350		—		—
Total	$	24,059,141	$	24,059,141	$	—	$	—

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the three months ended March 31, 2020 and year ended December 31, 2019. The carrying amount of the Company’s receivables and payables approximate their fair values due to their short maturities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventories

Note 7. Inventories

As of March 31, 2020 and December 31, 2019, inventories consisted of the following:

	March 31,			December 31,
	2020			2019
Raw materials	$	1,984,532		$	1,065,345
Work in process		4,582,175			5,314,763
Finished goods		345,103			531,064
Total inventory		6,911,810			6,911,172
Less: noncurrent		(6,247,439	)		(6,020,180	)
Total - current	$	664,371		$	890,992

As of March 31, 2020 and December 31, 2019, the Company’s reserves for obsolete inventory totaled $287,544. The Company records charges for obsolete inventory in cost of goods sold. Noncurrent inventory is comprised of approximately $1.8 million of raw materials and $4.4 million of work in process.

Property and Equipment - Net

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Property and Equipment - Net

Note 8. Property and Equipment – Net

Property and equipment, net, as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31,			December 31,
	2020			2019
Machinery and equipment	$	393,154		$	393,154
Furniture and fixture		309,190			310,820
Computer equipment		20,783			20,783
Leasehold Improvements		8,880			8,880
Property and equipment - gross		732,007			733,637
Less accumulated depreciation and amortization		(415,301	)		(388,401	)
Property and equipment - net	$	316,706		$	345,236

Property and equipment depreciation and amortization expense for the three months ended March 31, 2020 and 2019 was $26,900 and $25,522, respectively.

Leases

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Leases

Note 9. Leases

For the three months ended March 31, 2020 and 2019, the Company recognized lease expense of $119,650 and $199,654, respectively. This expense does not include non-lease components associated with the lease agreements as the Company elected not to include such charges as part of the lease expense.

The tables below provide the details of the right of use assets and lease liabilities:

Supplemental Balance Sheet Information for Operating Leases

	March 31, 2020			December 31, 2019
Operating leases:
Operating lease right of use assets	$	1,336,508		$	1,430,641
Operating lease liabilities:
Current portion of operating lease liabilities		514,917			486,445
Noncurrent operating lease liabilities		1,282,827			1,419,880
Total operating lease liabilities	$	1,797,744		$	1,906,325
Weighted average remaining lease term (in years)		5.8			5.9
Weighted average discount rate		13.75	%		13.75	%

Supplemental Statement of Cash Flows Information for Operating Leases

	Three months ended
	March 31, 2020			March 31, 2019
Noncash lease expense	$	87,000		$	70,315
Change in operating lease liabilities	$	(108,581	)	$	47,264

Future minimum lease payments under non-cancellable operating leases as of March 31, 2020:

Remainder of 2020	$	487,694
2021		743,818
2022		337,254
2023		142,892
2024 and thereafter		822,304
Total future minimum lease payments		2,533,962
Less: Amounts representing interest		(736,218	)
Total	$	1,797,744

Cloud Computing Arrangement

3 Months Ended

Mar. 31, 2020

Cloud Computing Arrangement [Abstract]

Cloud Computing Arrangement

Note 10. Cloud Computing Arrangement

In 2018, the Company entered into a contract to obtain a cloud computing arrangement (“CCA”). In accordance with ASU 2018-15, the implementation costs incurred in the CCA are deferred and recognized as other assets and are amortized to expense over the noncancelable term of the arrangement. The implementation of this CCA was completed on June 30, 2019. Beginning July 1, 2019, the Company went live with the cloud computing Enterprise Resource Planning system and all future related costs are expensed as incurred. In July 2019, the Company began amortizing the related deferred costs over the remaining period of the noncancelable arrangement. Amortization costs for the three months ended March 31, 2020 were $70,519. As of March 31, 2020, and December 31, 2019 the net book value of the CCA was $1,010,776 and $1,081,284 respectively.

Accrued Expenses

3 Months Ended

Mar. 31, 2020

Payables And Accruals [Abstract]

Accrued Expenses

Note 11. Accrued Expenses

Accrued expenses as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31,		December 31,
	2020		2019
Accrued professional fees		533,793		1,255,494
Accrued bonuses		759,308		804,082
Other accrued expenses		1,893,223		1,277,803
	$	3,186,324	$	3,337,379

Note Payable

3 Months Ended

Mar. 31, 2020

Notes Payable [Abstract]

Note Payable

Note 12. Note Payable

Finance and Security Agreement

On July 1, 2019, the Company entered into a Commercial Insurance Premium Finance and Security Agreement, or the Financing Agreement. The Financing Agreement provided for a single borrowing by the Company of $807,347, with a seven-month term, and an annual interest rate of 2.99%. The proceeds from this transaction were used to partially fund the premiums due under some of the Company’s insurance policies. The amounts payable were secured by the Company’s rights under such policies. During the three months ended March 31, 2020, the Company recognized $4,609 in interest expense. All borrowings were fully repaid as of March 31, 2020.

Stock Purchase Agreement

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stock Purchase Agreement

Note 13. Stock Purchase Agreement

On March 27, 2020, the Company and Lincoln Park entered into an equity facility purchase agreement pursuant to which the Company has the right to sell to Lincoln Park shares of common stock having an aggregate value of up to $25,000,000, subject to certain limitations and conditions set forth in the purchase agreement.

In consideration for entering into the purchase agreement with Lincoln Park, the Company issued an aggregate of 461,676 shares of common stock to Lincoln Park as a commitment fee. In addition, the Company will issue to Lincoln Park an aggregate of 230,838 additional shares of common stock as a further commitment fee based on the first $5,000,000 of shares of common stock issued to Lincoln Park under the Purchase Agreement as Purchase Shares (as such term is defined in the purchase agreement with Lincoln Park). The Company will not receive any cash proceeds from the issuance of any of the foregoing commitment shares.

The net proceeds under the purchase agreement to the Company will depend on the frequency and prices at which shares of common stock are sold to Lincoln Park. Actual sales of shares of common stock to Lincoln Park under the purchase agreement and the amount of such net proceeds will depend on a variety of factors, including market conditions, the trading price of the common stock and determinations by the Company as to other available and appropriate sources of funding for the Company. The Company expects to use the proceeds from this agreement for general corporate purposes and working capital. In April 2020, the Company sold 3,200,000 shares of the Company’s common stock under its purchase agreement with Lincoln Park, resulting in aggregate proceeds of approximately $3.2 million to the Company. -See Note 21. Subsequent Events

Net Loss Per Share

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net Loss Per Share

Note 14. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock awards and units, and stock options have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect.

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

	March 31,
	2020		2019
Outstanding stock options		3,808,563		2,901,970
Nonvested restricted stock and unit awards		1,094,825		1,608,434
Stock purchase warrants		62,181		62,181

Variable Interest Entity

3 Months Ended

Mar. 31, 2020

Variable Interest Entity [Abstract]

Variable Interest Entity

Note 15. Variable Interest Entity

As discussed in Note 1, electroCore is the primary beneficiary of electroCore Australia. In return for a 50% interest in such entity, electroCore has contributed certain intellectual property rights; all rights to distribute, market and sell specified products in Australia and New Zealand; and other rights outlined in the shareholders’ deed of electroCore Australia. In addition, electroCore can also appoint two of electroCore Australia’s four directors and can exercise significant influence over it. This along with the fact that electroCore is electroCore Australia’s only supplier causes electroCore, for accounting purposes, to be beneficiary of electroCore Australia. The activities related to electroCore Australia are not material to the consolidated financial statements.

Income Taxes

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Taxes

Note 16. Income Taxes

There is no provision for income taxes for the three months ended March 31, 2020 and 2019. The Company has incurred U.S. operating losses since inception and has not incurred any other income taxes. On March 27, 2020 the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. The CARES Act, among other things, includes certain tax provisions for individuals and corporations; however, the benefits do not impact the Company’s current tax provision.

Stock Based Compensation

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock Based Compensation

Note 17. Stock Based Compensation

The following table presents a summary of stock options granted:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, January 1, 2020		3,131,266		$	8.53		8.9	*
Granted		861,257			1.50
Exercised		—			—
Cancelled		(183,960	)		8.86
Outstanding, March 31, 2020		3,808,563		$	8.91		8.7	*
Exercisable, March 31, 2020		1,819,443		$	12.08		8.3	*
* de minimis

The intrinsic value is calculated as the difference between the fair market value at March 31, 2020 and the exercise price per share of the stock options. The options generally vest over a four-year period.

The following table presents a summary of restricted stock awards granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested January 1, 2020		127,505		$	8.09
Granted		—			—
Vested		(7,836	)		15.00
Cancelled		(11,049	)		9.65
Nonvested, March 31, 2020		108,620		$	7.43

In general, restricted stock awards vest over four years.

The following table presents a summary of restricted and deferred stock units, or Stock Units granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, January 1, 2020		1,241,493		$	2.86
Granted		94,640			1.15
Vested		(135,617	)		1.95
Cancelled		(214,311	)		4.27
Nonvested, March 31, 2020		986,205		$	2.51

In general, Stock Units vest over two to four years.

The Company recognized stock compensation for its equity awards as follows:

	Three months ended
	March 31, 2020		March 31, 2019
Selling, general and administrative	$	547,090	$	438,761
Research and development	$	186,599		276,556
Cost of goods sold	$	11,176		28,715

Total unrecognized compensation cost related to unvested awards as of March 31, 2020 was $6.4 million and is expected to be recognized over the next 2.6 years.

Valuation Information for Stock-Based Compensation

The fair value of each stock option award during the three months ended March 31, 2020 and 2019 was estimated on the date of grant using the Black-Scholes model. Expected volatility was based on historical volatility of the Company’s common stock. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembles the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the periods presented were:

	Three months ended March 31, 2020		Three months ended March 31, 2019
Fair value at grant date	$	1.27	$	4.89
Expected volatility	113.4%		84.6%
Risk-free interest rate	1.4%		2.4%
Expected holding period, in years	6.1		5.5
Dividend yield		—		—

Employee Stock Purchase Plan

3 Months Ended

Mar. 31, 2020

Compensation And Retirement Disclosure [Abstract]

Employee Stock Purchase Plan

Note 18. Employee Stock Purchase Plan

On January 1, 2019, the Company adopted the 2019 Employee Stock Purchase Plan, or the ESPP, which was approved by stockholder vote at the 2019 Annual Meeting of Stockholders held on June 7, 2019. The plan provided eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which were included in other current liabilities until they are used to purchase Company shares. On January 1, 2020 the Company terminated the ESPP. The common stock issuable in respect of the second bi-annual period under the plan were issued to eligible participating employees during the first quarter of 2020.

No expense was recognized for the ESPP for the quarters ended March 31, 2020 and 2019.

Restructuring and Other Severance Related Payments

3 Months Ended

Mar. 31, 2020

Restructuring And Related Activities [Abstract]

Restructuring and Other Severance Related Payments

Note 19. Restructuring and Other Severance Related Payments

In January 2020, the Company entered into a separation agreement with a former officer. This agreement requires a severance payment of $190,000 over a six-month period.

In January 2020, the Company entered into an agreement with a new employee that requires the unconditional payment of $175,000, in lieu of future severance. Payment is to be made in equal monthly installments over a fourteen-month period.

During the three months ended March 31, 2020, the Company recorded a charge of $365,000 in connection with these agreements. This expense is classified as restructuring and other severance related expense on its consolidated statements of operations.

As of March 31, 2020, $264,167 is owed by the Company under these agreements. This amount is classified under accrued liabilities on its balance sheet.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 20. Commitments and Contingencies

Stockholders Litigation

On July 8, 2019 and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which are proceeding under Docket No. SOM-L 000876-19. Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees. On October 31, 2019, the Company filed a motion to dismiss the complaint or in the alternative to stay the action in favor of the pending federal action (discussed below). On February 21, 2020 the court granted the defendants’ motion to dismiss the consolidated amended complaint with prejudice. On March 2, 2020 the court entered an amended order dismissing the consolidated amended complaint with prejudice. On March 27, 2020, the plaintiffs filed a notice of appeal with the N.J. Superior Court-Appellate Division.

On September 26, 2019 and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each allege that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints seek unspecified compensatory damages, interest, costs and attorneys’ fees.

In the Turnofsky case, on November 25, 2019 several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. The Priewe case was voluntarily dismissed on February 19, 2020.

The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgements or settlements that could adversely affect the Company’s financial condition.

The Company expenses associated legal fees in the period in which they are incurred.

Settlement Agreement

In January 2019, the Company settled a dispute with one of its former advisors, Madison Global Partners, who had filed a complaint against the Company in the Supreme Court of the State of New York, County of New York (Index No. 652329/2018). As part of that settlement, the Company paid Madison Global $325,000 and issued to Madison Global and its representatives warrants to purchase in the aggregate 62,181 shares of its common stock at prices ranging from $5.68 per share to $12.60 per share. In January 2019, 5,192 warrants with an exercise price of $5.68 were issued and the expense was recognized. All other amounts were accrued in prior accounting periods. The warrants issued are shown in the following table:

# Warrants		Exercise Price		Expiration Dates
	8,576	$	8.86	April 1, 2021
	22,253	$	5.68	March 30, 2022
	17,066	$	12.60	June 30, 2022
	14,286	$	12.60	August 31, 2022

Subsequent Events

3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

Note 21. Subsequent Events

Sales of Stock

In April 2020, the Company sold 3,200,000 shares of the Company’s common stock under its purchase agreement with Lincoln Park, resulting in aggregate proceeds of approximately $3.2 million to the Company. In connection with this sale, the Company issued an additional 149,454 shares of its common stock to Lincoln Park as a commitment fee under the purchase agreement.

On April 14, 2020, the Company entered into a Securities Purchase Agreement, or the Agreement, with certain accredited investors named in the Agreement (collectively, the Purchasers, pursuant to which the Company agreed to sell an aggregate of 2,058,822 shares to the Purchasers at a purchase price of $0.85 per share, or the Private Placement, for aggregate proceeds to the Company of approximately $1.75 million. Each of the Purchasers was an affiliate and/or existing shareholder of the Company, including some members of the Company’s board of directors. The Agreement contained customary representations, warranties and covenants of the Company and the Purchasers. In addition, the Purchasers were granted registration rights as further described in the Agreement.

On May 14, 2020, the Company entered into a Securities Purchase Agreement, or the Agreement, with its legal counsel pursuant to which the Company agreed to issue 1,564,345 shares of common stock, at a purchase price of $0.99 per share. Upon issuance of the shares, certain outstanding financial obligations of the Company owed to its legal counsel will be deemed paid and satisfied in full. The Agreement contains customary representations, warranties and covenants of the Company and its legal counsel, and the closing of the Agreement is subject to customary closing conditions. In addition, the Company’s legal counsel was granted customary registration rights.

Loan Under the Paycheck Protection Program

On May 4, 2020, the Company received proceeds of $1,409,300 in connection with a promissory note, or the Note, entered into with Citibank, N.A., evidencing an unsecured loan, or the Loan, under the Paycheck Protection Program, or the PPP. The PPP is a program of the U.S. Small Business Administration, or the SBA, established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). Under the PPP, the proceeds of the Loan may be used to pay payroll and make certain covered interest payments, lease payments and utility payments, or Qualifying Expenses. The Company intends to use the entire Loan amount for Qualifying Expenses under the PPP.

The interest rate on the Loan is 1.0% per annum. The Note matures on May 2, 2022. On December 2, 2020, or the First Payment Date, the Company is required to pay all accrued interest under the Loan that is not forgiven in accordance with the terms of the PPP. Additionally, on the First Payment Date and on the second day of each month thereafter until May 2, 2022, the Company must make equal monthly payments of the amount of principal under the Loan that is not forgiven in accordance with the terms of the PPP and related accrued interest thereon. The Note contains events of default and other conditions customary for a Note of this type.

Under the terms of the CARES Act, PPP loan recipients can be granted forgiveness for all or a portion of the loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of Qualifying Expenses and the Company maintaining its payroll levels over certain required thresholds under the PPP. The terms of any forgiveness also may be subject to further requirements in any regulations and guidelines the SBA may adopt. No assurance can be provided that the Company will obtain forgiveness of the Note in whole or in part. Official guidance and interpretations of the requirements of the program have been limited and have been changing over time. Despite the Company’s good-faith belief that it properly satisfied all eligibility requirements for the PPP loan, there has been increasing scrutiny of public companies that received loans, and there can be no assurance that the Company will not become subject to regulatory or other scrutiny, including a request or requirement for re-payment of some or all of the loan.

Sale of New Jersey net operating losses

On May 6, 2020, in connection with the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, the Company received approximately $1.2 million for the sale of approximately $13.9 million of its New Jersey net operating losses.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation

(a)	Basis of Presentation

Principles of Consolidation

(b)	Principles of Consolidation

Use of Estimates

(c)	Use of Estimates

Credit Loss Financial Instrument

(d)	Credit Losses on Financial Instruments

Fair Value Measurement

(e)	Fair Value Measurement

Recent Accounting Pronouncements Not Yet Adopted

(f)	Recent Accounting Pronouncements Not Yet Adopted

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Revenue From Contract With Customer [Abstract]

Summary of Net Sales Disaggregated by Geographic Area

The following table presents net sales disaggregated by geographic area:

	For the three months ended March 31,
	2020		2019
Geographic Market
United States	$	457,559	$	276,465
United Kingdom		245,466		90,584
Germany		30,746		35,836
Other		-		6,716
Total Net Sales	$	733,771	$	409,601

Cash, Cash Equivalents, and Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2020

Investments Debt And Equity Securities [Abstract]

Summary of Cash, Cash Equivalents, and Marketable Securities

The following tables summarize the Company’s cash, cash equivalents and marketable securities as of March 31, 2020 and December 31, 2019.

As of March 31, 2020
	Amortized Cost		Unrealized Gain		Unrealized (Loss)		Fair Value
Cash and cash equivalents	$	15,614,320	$	6,176	$	—	$	15,620,496

As of December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized (Loss)			Fair Value
Cash and cash equivalents	$	13,564,252	$	—	$	(461	)	$	13,563,791

U.S. Treasury Bonds	$	10,494,539	$	811	$	-		$	10,495,350
Total marketable securities	$	10,494,539	$	811	$	-		$	10,495,350

Total cash, cash equivalents, and marketable securities	$	24,058,791	$	811	$	(461	)	$	24,059,141

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Summary of Assets and Liabilities Carried at Fair Value

A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows:

			Fair Value Hierarchy
March 31, 2020	Total		Level 1		Level 2		Level 3
Assets
Cash and cash equivalents	$	15,620,496	$	15,620,496	$	—	$	—
Total	$	15,620,496	$	15,620,496	$	—	$	—

December 31, 2019
Assets
Cash and cash equivalents	$	13,563,791	$	13,563,791	$	—	$	—
Marketable Securities:
U.S. treasury bonds		10,495,350		10,495,350		—		—
Total	$	24,059,141	$	24,059,141	$	—	$	—

Inventories (Tables)

3 Months Ended

Mar. 31, 2020

Inventory Disclosure [Abstract]

Inventories Stated at Lower of Cost or Market

As of March 31, 2020 and December 31, 2019, inventories consisted of the following:

	March 31,			December 31,
	2020			2019
Raw materials	$	1,984,532		$	1,065,345
Work in process		4,582,175			5,314,763
Finished goods		345,103			531,064
Total inventory		6,911,810			6,911,172
Less: noncurrent		(6,247,439	)		(6,020,180	)
Total - current	$	664,371		$	890,992

Property and Equipment - Net (Tables)

3 Months Ended

Mar. 31, 2020

Property Plant And Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net, as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31,			December 31,
	2020			2019
Machinery and equipment	$	393,154		$	393,154
Furniture and fixture		309,190			310,820
Computer equipment		20,783			20,783
Leasehold Improvements		8,880			8,880
Property and equipment - gross		732,007			733,637
Less accumulated depreciation and amortization		(415,301	)		(388,401	)
Property and equipment - net	$	316,706		$	345,236

Leases (Tables)

3 Months Ended

Mar. 31, 2020

Leases [Abstract]

Supplemental Balance Sheet Information for Operating Leases

	March 31, 2020			December 31, 2019
Operating leases:
Operating lease right of use assets	$	1,336,508		$	1,430,641
Operating lease liabilities:
Current portion of operating lease liabilities		514,917			486,445
Noncurrent operating lease liabilities		1,282,827			1,419,880
Total operating lease liabilities	$	1,797,744		$	1,906,325
Weighted average remaining lease term (in years)		5.8			5.9
Weighted average discount rate		13.75	%		13.75	%

Supplemental Statement of Cash Flows Information for Operating Leases

	Three months ended
	March 31, 2020			March 31, 2019
Noncash lease expense	$	87,000		$	70,315
Change in operating lease liabilities	$	(108,581	)	$	47,264

Future Minimum Lease Payments under Non-Cancellable Operating Leases

Future minimum lease payments under non-cancellable operating leases as of March 31, 2020:

Remainder of 2020	$	487,694
2021		743,818
2022		337,254
2023		142,892
2024 and thereafter		822,304
Total future minimum lease payments		2,533,962
Less: Amounts representing interest		(736,218	)
Total	$	1,797,744

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2020

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses as of March 31, 2020 and December 31, 2019 consisted of the following:

	March 31,		December 31,
	2020		2019
Accrued professional fees		533,793		1,255,494
Accrued bonuses		759,308		804,082
Other accrued expenses		1,893,223		1,277,803
	$	3,186,324	$	3,337,379

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

	March 31,
	2020		2019
Outstanding stock options		3,808,563		2,901,970
Nonvested restricted stock and unit awards		1,094,825		1,608,434
Stock purchase warrants		62,181		62,181

Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Options Granted Activity

The following table presents a summary of stock options granted:

	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)		Aggregate Intrinsic Value
Outstanding, January 1, 2020		3,131,266		$	8.53		8.9	*
Granted		861,257			1.50
Exercised		—			—
Cancelled		(183,960	)		8.86
Outstanding, March 31, 2020		3,808,563		$	8.91		8.7	*
Exercisable, March 31, 2020		1,819,443		$	12.08		8.3	*
* de minimis

Summary of Restricted Stock Awards Granted Activity

The following table presents a summary of restricted stock awards granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested January 1, 2020		127,505		$	8.09
Granted		—			—
Vested		(7,836	)		15.00
Cancelled		(11,049	)		9.65
Nonvested, March 31, 2020		108,620		$	7.43

Summary of Restricted Stock and Deferred Stock Units Granted Activity

The following table presents a summary of restricted and deferred stock units, or Stock Units granted:

	Number of Shares			Weighted Average Grant Date Fair Value
Nonvested, January 1, 2020		1,241,493		$	2.86
Granted		94,640			1.15
Vested		(135,617	)		1.95
Cancelled		(214,311	)		4.27
Nonvested, March 31, 2020		986,205		$	2.51

Schedule of Recognized Stock Compensation for Equity Awards

The Company recognized stock compensation for its equity awards as follows:

	Three months ended
	March 31, 2020		March 31, 2019
Selling, general and administrative	$	547,090	$	438,761
Research and development	$	186,599		276,556
Cost of goods sold	$	11,176		28,715

Summary of Weighted Average Assumptions Used in Valuing Plans

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the periods presented were:

	Three months ended March 31, 2020		Three months ended March 31, 2019
Fair value at grant date	$	1.27	$	4.89
Expected volatility	113.4%		84.6%
Risk-free interest rate	1.4%		2.4%
Expected holding period, in years	6.1		5.5
Dividend yield		—		—

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Schedule of Warrants Issued

# Warrants		Exercise Price		Expiration Dates
	8,576	$	8.86	April 1, 2021
	22,253	$	5.68	March 30, 2022
	17,066	$	12.60	June 30, 2022
	14,286	$	12.60	August 31, 2022

Risks and Uncertainties - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	May 06, 2020	May 04, 2020	Jul. 01, 2019	Apr. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 27, 2020
Risks And Uncertainties [Line Items]
Net losses					$ 7,959,349	$ 13,861,530	$ 45,100,000	$ 55,800,000
Accumulated deficit					$ 91,438,447		$ 83,479,098
Proceeds from promissory note			$ 807,347
Net Sales \| Government Contracts Concentration Risk
Risks And Uncertainties [Line Items]
Percentage of net sales					95.00%	30.00%
Subsequent Event \| Promissory Note \| Citibank, N.A. \| Paycheck Protection Program
Risks And Uncertainties [Line Items]
Proceeds from promissory note		$ 1,409,300
Stock Purchase Agreement \| Lincoln Park
Risks And Uncertainties [Line Items]
Value of shares issued									$ 5,000,000
Stock Purchase Agreement \| Lincoln Park \| Subsequent Event
Risks And Uncertainties [Line Items]
Aggregate proceeds from sale of common stock				$ 3,200,000
Stock Purchase Agreement \| Lincoln Park \| Subsequent Event \| Private Placement Transaction
Risks And Uncertainties [Line Items]
Aggregate proceeds from sale of common stock				$ 5,000,000
Stock Purchase Agreement \| Lincoln Park \| Maximum
Risks And Uncertainties [Line Items]
Value of shares issued									$ 25,000,000
New Jersey Technology Business Tax Certificate Transfer (NOL) Program \| Subsequent Event
Risks And Uncertainties [Line Items]
Sale of net operating losses	$ 1,200,000

Revenue Recognition - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 733,771	$ 409,601
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	457,559	276,465
United Kingdom
Disaggregation Of Revenue [Line Items]
Total Net Sales	245,466	90,584
Germany
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 30,746	35,836
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales		$ 6,716

Revenue Recognition - Additional Information (Details)	3 Months Ended
Revenue Recognition - Additional Information (Details)	Mar. 31, 2020 USD ($)
Revenue From Contract With Customer [Abstract]
Revenue remaining unsatisfied performance obligation	$ 0
Payment term for customers	120 days

Cash, Cash Equivalents, and Marketable Securities - Summary of Cash, Cash Equivalents, and Marketable Securities (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Cash and Cash Equivalents, Amortized Cost	$ 15,614,320	$ 13,564,252
Cash and Cash Equivalents, Unrealized Gain	6,176
Cash and Cash Equivalents, Unrealized (Loss)		(461)
Cash and cash equivalents	15,620,496	13,563,791
Marketable securities, Amortized Cost		10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Fair Value		10,495,350
Cash, cash equivalents and marketable securities, Amortized Cost		24,058,791
Cash, cash equivalents and marketable securities, Unrealized Gain		811
Cash, cash equivalents, and marketable securities, Unrealized (Loss)		(461)
Cash, cash equivalents, and marketable securities, Fair Value	$ 15,620,496	24,059,141
U.S. Treasury Bonds
Schedule Of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost		10,494,539
Marketable securities, Unrealised Gain		811
Marketable securities, Fair Value		10,495,350
Cash, cash equivalents, and marketable securities, Fair Value		$ 10,495,350

Fair Value Measurements - Summary of Assets and Liabilities Carried at Fair Value (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 15,620,496	$ 13,563,791
Marketable Securities	15,620,496	24,059,141
U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		10,495,350
(Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	15,620,496	13,563,791
Marketable Securities	$ 15,620,496	24,059,141
(Level 1) \| U.S. Treasury Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable Securities		$ 10,495,350

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value of assets, transfer from level 1 to level 2	$ 0	$ 0
Fair value of assets transfer from level 2 to level 1	0	0
Fair value of liabilities, transfer from level 1 to level 2	0	0
Fair value of liabilities, transfer from level 2 to level 1	0	0
Fair value of assets, transfers into level 3	0	0
Fair value of assets, transfers out of level 3	0	0
Fair value of liabilities, transfers Into level 3	0	0
Fair value of liabilities, transfers out of level 3	$ 0	$ 0

Inventory - Inventories Stated at Lower of Cost or Market (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,984,532	$ 1,065,345
Work in process	4,582,175	5,314,763
Finished goods	345,103	531,064
Total inventory	6,911,810	6,911,172
Less: noncurrent	(6,247,439)	(6,020,180)
Total - current	$ 664,371	$ 890,992

Inventory - Additional Information (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Inventory [Line Items]
Noncurrent inventory raw materials	$ 1,800,000	$ 1,800,000
Noncurrent inventory work in process	4,400,000	4,400,000
Inventory Valuation and Obsolescence [Member]
Inventory [Line Items]
Inventory raw materials	$ 287,544	$ 287,544

Property and Equipment - Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 732,007	$ 733,637
Less accumulated depreciation and amortization	(415,301)	(388,401)
Property and equipment - net	316,706	345,236
Machinery and Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	393,154	393,154
Furniture and Fixture
Property Plant And Equipment [Line Items]
Property and equipment - gross	309,190	310,820
Computer Equipment
Property Plant And Equipment [Line Items]
Property and equipment - gross	20,783	20,783
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment - gross	$ 8,880	$ 8,880

Property and Equipment - Net - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 26,900	$ 25,522

Leases - Additional Information (Details) - USD ($)	3 Months Ended
Leases - Additional Information (Details) - USD ($)	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Recognized lease expenses	$ 119,650	$ 199,654

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Operating leases:
Operating lease right of use assets	$ 1,336,508	$ 1,430,641
Current portion of operating lease liabilities	514,917	486,445
Noncurrent operating lease liabilities	1,282,827	1,419,880
Total operating lease liabilities	$ 1,797,744	$ 1,906,325
Weighted average remaining lease term (in years)	5 years 9 months 18 days	5 years 10 months 24 days
Weighted average discount rate	13.75%	13.75%

Leases - Supplemental Statement of Cash Flows Information for Operating Leases (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Noncash lease expense	$ 87,000	$ 70,315
Change in operating lease liabilities	$ (108,581)	$ 47,264

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 487,694
2021	743,818
2022	337,254
2023	142,892
2024 and thereafter	822,304
Total future minimum lease payments	2,533,962
Less: Amounts representing interest	(736,218)
Total	$ 1,797,744	$ 1,906,325

Cloud Computing Arrangement - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Cloud Computing Arrangement [Abstract]
Amortization of cloud computing arrangement	$ 70,519
Net book value of cloud computing arrangement	$ 1,010,776	$ 1,081,284

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 533,793	$ 1,255,494
Accrued bonuses	759,308	804,082
Other accrued expenses	1,893,223	1,277,803
Accrued expenses	$ 3,186,324	$ 3,337,379

Note Payable - Additional Information (Details) - USD ($)		3 Months Ended
	Jul. 01, 2019	Mar. 31, 2020
Notes Payable [Line Items]
Proceeds from borrowings	$ 807,347
Debt instrument balance fully repaid		Mar. 31, 2020
Note Payable
Notes Payable [Line Items]
Debt instrument, term	7 months
Debt instrument, annual interest rate	2.99%
Interest expense		$ 4,609

Stock Purchase Agreement - Additional Information (Details) - USD ($)	1 Months Ended
	Apr. 30, 2020	Mar. 31, 2020	Mar. 27, 2020	Dec. 31, 2019
Stock Purchase Agreement [Line Items]
Common stock, shares issued		30,421,427		29,835,183
Stock Purchase Agreement \| Lincoln Park
Stock Purchase Agreement [Line Items]
Value of shares issued			$ 5,000,000
Common stock, shares issued			461,676
Stock Purchase Agreement \| Lincoln Park \| Subsequent Event
Stock Purchase Agreement [Line Items]
Common stock, shares issued	3,200,000
Additional commitment shares issued	149,454
Aggregate proceeds from sale of common stock	$ 3,200,000
Stock Purchase Agreement \| Lincoln Park \| Maximum
Stock Purchase Agreement [Line Items]
Value of shares issued			$ 25,000,000
Additional commitment shares issued			230,838

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	3,808,563	2,901,970
Nonvested restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,094,825	1,608,434
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	62,181	62,181

Variable Interest Entity - Additional Information (Details) - ElectroCore (Aust) Pty Limited	3 Months Ended
	Mar. 31, 2020 Director
Variable Interest Entity [Line Items]
Variable interest entity ownership percentage	50.00%
Number of directors	4
Number of directors appoint	2

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 0	$ 0

Stock Based Compensation - Summary of Stock Options Granted Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Options, Outstanding, January 1, 2020	3,131,266
Number of Options, Granted	861,257
Number of Options, Cancelled	(183,960)
Number of Options, Outstanding, March 31, 2020	3,808,563	3,131,266
Number of Options, Exercisable, March 31, 2020	1,819,443
Weighted Average Exercise Price, Outstanding, January 1, 2020	$ 8.53
Weighted Average Exercise Price, Granted	1.50
Weighted Average Exercise Price, Cancelled	8.86
Weighted Average Exercise Price, Outstanding, March 31, 2020	8.91	$ 8.53
Weighted Average Exercise Price, Exercisable, March 31, 2020	$ 12.08
Weighted Average Remaining Contractual Term (Years), Outstanding, January 1, 2020	8 years 8 months 12 days	8 years 10 months 24 days
Weighted Average Remaining Contractual Term (Years), Exercisable, March 31, 2020	8 years 3 months 18 days

Stock Based Compensation - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Unrecognized compensation cost related to unvested awards	$ 6.4
Unrecognized compensation expected to be recognized	2 years 7 months 6 days
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Stock Units \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Stock Units \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Stock Based Compensation - Summary of Restricted Stock Awards Granted Activity (Details) - Restricted Stock Awards	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 \| shares	127,505
Number of Shares, Vested \| shares	(7,836)
Number of Shares, Cancelled \| shares	(11,049)
Number of Shares, Nonvested, March 31, 2020 \| shares	108,620
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 \| $ / shares	$ 8.09
Weighted Average Grand Date Fair Value, Vested \| $ / shares	15.00
Weighted Average Grand Date Fair Value, Cancelled \| $ / shares	9.65
Weighted Average Grand Date Fair Value, Nonvested, March 31, 2020 \| $ / shares	$ 7.43

Stock Based Compensation - Summary of Restricted Stock and Deferred Stock Units Granted Activity (Details) - Stock Units	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Nonvested, January 1,2020 \| shares	1,241,493
Number of Shares, Granted \| shares	94,640
Number of Shares, Vested \| shares	(135,617)
Number of Shares, Cancelled \| shares	(214,311)
Number of Shares, Nonvested, March 31, 2020 \| shares	986,205
Weighted Average Grand Date Fair Value, Nonvested, January 1, 2020 \| $ / shares	$ 2.86
Weighted Average Grand Date Fair Value, Granted \| $ / shares	1.15
Weighted Average Grand Date Fair Value, Vested \| $ / shares	1.95
Weighted Average Grand Date Fair Value, Cancelled \| $ / shares	4.27
Weighted Average Grand Date Fair Value, Nonvested, March 31, 2020 \| $ / shares	$ 2.51

Stock Based Compensation - Schedule of Recognized Stock Compensation for Equity Awards (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 547,090	$ 438,761
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	186,599	276,556
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 11,176	$ 28,715

Stock Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Fair value at grant date	$ 1.27	$ 4.89
Expected volatility	113.40%	84.60%
Risk-free interest rate	1.40%	2.40%
Expected holding period, in years	6 years 1 month 6 days	5 years 6 months

Employee Stock Purchase Plan - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
2019 Employee Stock Purchase Plan
Defined Benefit Plan Disclosure [Line Items]
Expense recognized	$ 0	$ 0

Restructuring and Other Severance Related Payments - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring and other severance related expense		$ 365,000	$ 0
Accrued Liabilities
Restructuring Cost And Reserve [Line Items]
Amount owed under these agreements		$ 264,167
Employee Severance \| Former Officer
Restructuring Cost And Reserve [Line Items]
Severance payment	$ 190,000
Employee Severance \| New Employee
Restructuring Cost And Reserve [Line Items]
Severance payment	$ 175,000

Commitments and Contingencies - Additional Information (Details) - Former Financial Advisor	1 Months Ended
	Jan. 31, 2019 USD ($) Dispute $ / shares shares
Class Of Warrant Or Right [Line Items]
Number of dispute settled \| Dispute	1
Cash paid in settlement agreement \| $	$ 325,000
Common Stock
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock \| shares	62,181
Exercise price of warrants	$ 5.68
Common Stock \| Minimum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	5.68
Common Stock \| Maximum
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 12.60
Common Stock \| Warrants with Exercise Price of $5.68
Class Of Warrant Or Right [Line Items]
Warrants to purchase common stock \| shares	5,192

Commitments and Contingencies - Schedule of Warrants Issued (Details) - Former Financial Advisor	Jan. 31, 2019 $ / shares shares
Warrant One
Class Of Warrant Or Right [Line Items]
Number of Warrants \| shares	8,576
Exercise Price \| $ / shares	$ 8.86
Expiration Dates	Apr. 01, 2021
Warrant Two
Class Of Warrant Or Right [Line Items]
Number of Warrants \| shares	22,253
Exercise Price \| $ / shares	$ 5.68
Expiration Dates	Mar. 30, 2022
Warrant Three
Class Of Warrant Or Right [Line Items]
Number of Warrants \| shares	17,066
Exercise Price \| $ / shares	$ 12.60
Expiration Dates	Jun. 30, 2022
Warrant Four
Class Of Warrant Or Right [Line Items]
Number of Warrants \| shares	14,286
Exercise Price \| $ / shares	$ 12.60
Expiration Dates	Aug. 31, 2022

Subsequent Events - Additional Information (Details) - USD ($)						1 Months Ended	3 Months Ended
	May 14, 2020	May 06, 2020	May 04, 2020	Apr. 14, 2020	Jul. 01, 2019	Apr. 30, 2020	Mar. 31, 2020	Mar. 27, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Common stock, shares issued							30,421,427		29,835,183
Proceeds from promissory note					$ 807,347
Note, maturity date							Mar. 31, 2020
Subsequent Event \| Promissory Note \| Citibank, N.A. \| Paycheck Protection Program
Subsequent Event [Line Items]
Proceeds from promissory note			$ 1,409,300
Interest rate on the Loan			1.00%
Note, maturity date			May 02, 2022
Stock Purchase Agreement \| Lincoln Park
Subsequent Event [Line Items]
Common stock, shares issued								461,676
Stock Purchase Agreement \| Lincoln Park \| Subsequent Event
Subsequent Event [Line Items]
Common stock, shares issued						3,200,000
Aggregate proceeds from issuance of common stock						$ 3,200,000
Additional commitment shares issued						149,454
Securities Purchase Agreement \| Subsequent Event
Subsequent Event [Line Items]
Aggregate number of shares issued				2,058,822
Shares issued. price per share				$ 0.85
Aggregate proceeds from private placement				$ 1,750,000
Number of shares issued	1,564,345
Shares issued price per share	$ 0.99
New Jersey Technology Business Tax Certificate Transfer (NOL) Program \| Subsequent Event
Subsequent Event [Line Items]
Sale of net operating losses		$ 1,200,000
Net operating losses		$ 13,900,000